Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "contract-development-and-manufacturing-organisation"

13 News Found

Syngene signs 10-year biologics manufacturing agreement with Zoetis
News | July 15, 2022

Syngene signs 10-year biologics manufacturing agreement with Zoetis

Syngene's collaboration with Zoetis started in 2011

PharmaZell and Novasep come together to form a formidable API and CDMO platform
Biotech | September 17, 2021

PharmaZell and Novasep come together to form a formidable API and CDMO platform

They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale

Cipla forms JV with Kemwell Biopharma
News | August 25, 2021

Cipla forms JV with Kemwell Biopharma

The agreement is to develop, manufacture and commercialise biosimilars for the global market.

Upcoming E-conference
June 19, 2026 The Future of Clinical Research in India: Can India Become a Global Trial Hub?
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Moderna reshapes leadership and ops model as it pushes into oncology, rare disease

Siegfried opens major API manufacturing facility in Germany

Pharma PLI scheme attracted Rs. 42,694 crore investments, created 1.13 lakh jobs in 6 years: Govt

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Cancer treatment must move beyond one-size-fits-all decisions: Dr. Manjiri Bakre, CEO and Founder, OncoStem Diagnostics
Dr. Manjiri Bakre CEO and Founder, OncoStem Diagnostics
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene
Akhil Ravi Chief Executive Officer, Aurigene Pharmaceutical Services Limited
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation

Packaging